Blanca Sánchez-Robles

Oct 31, 2024 | onlinelibrary.wiley.com | Ricardo Diaz |Ricardo Díaz |Blanca Sánchez-Robles

1 Introduction The productivity of research in the biopharmaceutical industry is decreasing over time (Carter et al. 2016; Masri et al. 2012). While R&D expenditures escalate, the number of drug approvals by government agencies declines, in a context of rising competition, pressure by national health systems to reduce drug prices, and more restrictive regulations about clinical research (Ippoliti, Ramello, and Scherer 2021).

Feb 10, 2023 | dovepress.com | Ricardo Diaz |Teresa Herrador-Alcaide |Blanca Sánchez-Robles

IntroductionThe COVID-19 shock brought about large social and economic repercussions of various sorts. The pandemic disrupted different sectors and activities. Many effects of the pandemic have been already investigated and discussed. Others, such as the impact on the biopharmaceutical industry, are not well understood yet and deserve further attention. In general, health shocks generate two types of effect on biopharmaceutical firms.